<?xml version="1.0" encoding="UTF-8"?>
<p>Novel technologies aimed at promoting hemostasis in patients with hemophilia without replacing the deficient factor are currently in clinical development. These include FVIII mimics 
 <sup>
  <xref rid="ref-49" ref-type="bibr">49</xref>– 
  <xref rid="ref-52" ref-type="bibr">52</xref>
 </sup> and agents that obstruct the function of natural anti-coagulants, such as antithrombin (AT) 
 <sup>
  <xref rid="ref-53" ref-type="bibr">53</xref>, 
  <xref rid="ref-54" ref-type="bibr">54</xref>
 </sup>, tissue factor pathway inhibitor (TFPI) 
 <sup>
  <xref rid="ref-55" ref-type="bibr">55</xref>– 
  <xref rid="ref-59" ref-type="bibr">59</xref>
 </sup>, and activated protein C (APC) 
 <sup>
  <xref rid="ref-60" ref-type="bibr">60</xref>, 
  <xref rid="ref-61" ref-type="bibr">61</xref>
 </sup>.
</p>
